This content is intended for UK & ROI healthcare professionals. Not a healthcare professional? Return to audience selector.

Dose Table

Sialanar® is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.1 Adverse event reporting information can be found at the bottom of the page.

Dose table for children and adolescents with normal renal function (glycopyrronium bromide)1

Click on the patient's weight below to find the recommended dose

13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg

13-17 kg

  • Dose Level 1
    16 mcg/kg

    0.6ml

  • Dose Level 2
    32 mcg/kg

    1.2ml

  • Dose Level 3
    48 mcg/kg

    1.8ml

  • Dose Level 4
    64 mcg/kg

    2.4ml

  • Dose Level 5
    80 mcg/kg

    3ml*

* Maximum individual dose in this weight range.

Dose table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) (glycopyrronium bromide)1

Click on the patient's weight below to find the recommended dose

13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg

13-17 kg

  • Dose Level 1
    11 mcg/kg

    0.4ml

  • Dose Level 2
    22 mcg/kg

    0.8ml

  • Dose Level 3
    34 mcg/kg

    1.2ml

  • Dose Level 4
    45 mcg/kg

    1.7ml

  • Dose Level 5
    56 mcg/kg

    2.1ml*

* Maximum individual dose in this weight range.

Please refer to the SmPC for full dosing information

Request a printed dosing wheel

Submit this form to request a printed dosing wheel to support you or your team:

Safety

Head to this section for guidance on side effects and titration.

Safety

References

  1. Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301 – accessed December 2024
  2. Parr J.R, Todhunter E, Pennington L, et al. (2017) Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
  3. Reid S.M, et al. (2019) Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology; 63(3): 346-353

UK-SIA-25-0064 | October 2025

Adverse Event Reporting Information

UK: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. 

Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.

Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving this website and will be redirected to the Proveca.nl website.

Continue